Bringing the fundamentals into focus…
Back to Madrigal Pharmaceuticals, Inc.
How Madrigal Pharmaceuticals, Inc. stacks up
MDGL · against 170 other Healthcare companies of similar size
Overall
39/ 100
Near the bottom of its peers.
Ranked #138 of 171 · scores higher than 19% of peers
Bars: peers in each 10-point band of the overall score25 peers with an overall score of 30–39, including MDGL · Click a bar to see the companies
The four scores behind it
Overall = average of valuation, growth, profitability and safety percentile (categories without data are skipped)Ranking by overall score
Top 5 and the companies ranked around MDGL| Rank | Company | Market cap | Overall | Valuation | Growth | Profitability | Risk |
|---|---|---|---|---|---|---|---|
| 1 | 37.3B HKD (≈$4.8B) | 90 | 99 | 98 | 84 | 0 / 2 | |
| 2 | 921.9B INR (≈$11.1B) | 82 | 84 | 80 | 94 | 0 / 2 | |
| 3 | 936.1B JPY (≈$6.4B) | 80 | 65 | 86 | 94 | 0 / 2 | |
| 4 | 10.7B USD | 78 | 77 | 85 | 84 | 0 / 2 | |
| 4 | 9.0B USD | 78 | 50 | 80 | 94 | 0 / 2 | |
| 132 | 5.5B USD | 43 | 53 | 24 | 76 | 2 / 2 | |
| 135 | 4.7B USD | 42 | 30 | 95 | 34 | 2 / 2 | |
| 136 | 10.8B USD | 41 | 41 | 37 | 41 | 1 / 2 | |
| 137 | 18.2B USD | 40 | 48 | 29 | 56 | 2 / 2 | |
| 138 | 9.2B USD | 39 | 8 | 93 | 21 | 2 / 2 | |
| 138 | 5.9B USD | 39 | 44 | 36 | 53 | 2 / 2 | |
| 140 | 5.4B USD | 38 | 8 | — | 15 | 0 / 2 | |
| 140 | 5.7B USD | 38 | 44 | 9 | 86 | 2 / 2 | |
| 140 | 5.8B USD | 38 | 42 | 56 | 40 | 2 / 2 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score